Related references
Note: Only part of the references are listed.Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff et al.
CLINICAL CANCER RESEARCH (2016)
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Maite Verreault et al.
CLINICAL CANCER RESEARCH (2016)
Quantification of cell viability and rapid screening anti-cancer drug utilizing nanomechanical fluctuation
Shangquan Wu et al.
BIOSENSORS & BIOELECTRONICS (2016)
Characterizing Cellular Biophysical Responses to Stress by Relating Density, Deformability, and Size
Sangwon Byun et al.
BIOPHYSICAL JOURNAL (2015)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Joan Montero et al.
CELL (2015)
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Oliver Jonas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Precision medicine for cancer with next-generation functional diagnostics
Adam A. Friedman et al.
NATURE REVIEWS CANCER (2015)
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation
Andrew A. Lane et al.
NATURE GENETICS (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Joshua M. Francis et al.
CANCER DISCOVERY (2014)
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
Inconsistency in large pharmacogenomic studies
Benjamin Haibe-Kains et al.
NATURE (2013)
What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway
Samuel J. Klempner et al.
CANCER DISCOVERY (2013)
Direct observation of mammalian cell growth and size regulation
Sungmin Son et al.
NATURE METHODS (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Evidence for label-retaining tumour-initiating cells in human glioblastoma
Loic P. Deleyrolle et al.
BRAIN (2011)
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumour evolution inferred by single-cell sequencing
Nicholas Navin et al.
NATURE (2011)
Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
Justin D. Lathia et al.
PLOS ONE (2011)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Using buoyant mass to measure the growth of single cells
Michel Godin et al.
NATURE METHODS (2010)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Martin L. Sos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
Michael J. Pencina et al.
STATISTICS IN MEDICINE (2008)
Weighing of biomolecules, single cells and single nanoparticles in fluid
Thomas P. Burg et al.
NATURE (2007)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mechanisms of disease: Acute lymphoblastic leukemia
C Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
